Amylyx patent expiration

1. Relyvrio patent expiration

RELYVRIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11071742 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US10857162 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US10251896 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US9872865 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US11583542 AMYLYX Compositions of bile acids and phenylbutyrate compounds
Jul, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 29, 2027
Orphan Drug Exclusivity(ODE-411) Sep 29, 2029

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 29 September, 2026

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION

More Information on Dosage

RELYVRIO family patents

Family Patents